This dashboard provides a board-level view of portfolio coverage, quantified surveillance activity, and genome production indicators to support leadership review, operational oversight, and strategic planning.
A compact management summary of scope, activity, and where deeper operational detail currently exists.
Comparative view of where the current measured workload or activity is concentrated.
Highest positive counts in the available dataset.
| Pathogen | Program | Positives | Genome production |
|---|---|---|---|
| SARS-COV-2 | Influenza Program | 2,000 | 8% |
| Influenza A | Influenza Program | 1,600 | 10% |
| Staphylococcus aureus | PBIDS | 1,300 | 0% |
| Shigella spp | PBIDS | 1,200 | 0% |
| Non-typhoidal Salmonella | PBIDS | 875 | 0% |
| RSV | Influenza Program | 760 | 6% |
| Pseudomonas aeruginosa | PBIDS | 478 | 0% |
| Salmonella Typhi | PBIDS | 456 | 45% |
Portfolio snapshot showing both quantified programs and broader strategic areas represented within the current reporting structure.
Leadership view of the strongest genome production percentages in the current reporting extract.
Percent of genomes produced for the top detailed rows in the workbook.
This section can help management discuss sequencing output efficiency and identify where stronger conversion from positives to genomes may already exist.
The proportion of the listed program portfolio currently supported by quantitative detail in the available reporting extract.
Useful for showing current reporting coverage and identifying where broader portfolio data can further strengthen oversight.
Recommended leadership narrative:
Detailed view to support follow-up discussion, review, and decision-making.
| Program | Pathogen | Age category | Total positives | Genome production | Year established |
|---|---|---|---|---|---|
| Influenza Program | Influenza A | 3 months-65 Years | 1,600 | 10% | 2012 |
| Influenza Program | Influenza B | 3 months-65 Years | 386 | 13% | 2012 |
| Influenza Program | SARS-COV-2 | 3 months-65 Years | 2,000 | 8% | 2012 |
| Influenza Program | RSV | 3 months-65 Years | 760 | 6% | 2012 |
| PBIDS | Salmonella Typhi | 3 months-65 Years | 456 | 45% | 2007 |
| PBIDS | Shigella spp | 3 months-65 Years | 1,200 | 0% | 2007 |
| PBIDS | Enterococcus faecium | 3 months-65 Years | 283 | 0% | 2007 |
| PBIDS | Pseudomonas aeruginosa | 3 months-65 Years | 478 | 0% | 2007 |
| PBIDS | Non-typhoidal Salmonella | 3 months-65 Years | 875 | 0% | 2007 |
| PBIDS | Neisseria gonorrhoeae | 3 months-65 Years | 134 | 0% | 2007 |
| PBIDS | Staphylococcus aureus | 3 months-65 Years | 1,300 | 0% | 2007 |
| Entomology | — | — | — | — | — |
| Malaria | — | — | — | — | — |
| Neglected Tropical Diseases | — | — | — | — | — |
| TB | — | — | — | — | — |
| HIV-R | — | — | — | — | — |
| CHAMPS | — | — | — | — | — |